ZoomInfo Complaint Overview
The ZoomInfo class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in ZoomInfo securities. The class action is pending in the U.S. District Court for the Western District of Washington. It is captioned Tejeda v. ZoomInfo Technologies et al., No. 26-cv-05696.
If you lost money on your ZoomInfo investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.
Why is ZoomInfo Being Sued for Securities Fraud?
ZoomInfo has been sued for securities fraud following a significant stock drop resulting from potential violations of the federal securities laws. The decline in ZoomInfo’s stock price caused significant losses to investors.
ZoomInfo provides go-to-market (“GTM”) intelligence and a customer engagement platform for sales, marketing, operations, and recruiting professionals.
Throughout the relevant period, ZoomInfo allegedly stated that “the demand for AI for GTM is evident up and down our customer stack.” According to ZoomInfo, its “innovative go-to-market AI” was “driving stronger daily engagement from a diverse set of go-to-market personas.”
On February 9, 2026, ZoomInfo issued its 2026 revenue guidance “in the range of $1.247 billion to $1.267 billion,” because “in 2026, our focus is on bringing” ZoomInfo’s “all-in-one AI platform for go-to-market teams . . . to our customers at scale.”
In truth, as alleged, ZoomInfo’s customer retention declined as customers were rejecting ZoomInfo’s AI products.
Why did ZoomInfo’s Stock Drop?
On May 11, 2026, ZoomInfo announced its Q1 2026 results and slashed its 2026 revenue guidance from $1.247-$1.267 billion to $1.185-$1.205 billion. ZoomInfo revealed that its customer growth “regressed” due to “AI and agentic confusion” leading to “a pause in [customers’] purchasing decisions[.]”
This news caused the price of ZoomInfo stock to decline $1.98 per share, or 32.78%, from a closing price of $6.04 per share on May 11, 2026, to $4.06 per share on May 12, 2026.
ZoomInfo (GTM) Stock Chart
Image Caption: NASDAQ online chart showing the ZoomInfo (GTM) stock drop following the May 2026 announcement.
What is the ZoomInfo Leadership Deadline?
You may ask the Court no later than August 24, 2026, to appoint you as Lead Plaintiff through counsel of your choice.
To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.
How Do I Submit My Information?
If you lost money when ZoomInfo securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.
You can also contact:
Adam McCall
amccall@bfalaw.com
212.789.3619
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of any class action lawsuit. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS.
BFA attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
